Danicopan
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Danicopan, sold under the brand name Voydeya, is a medication used for the treatment of paroxysmal nocturnal hemoglobinuria. It is a complement inhibitor which reversibly binds to factor D to prevent alternative pathway-mediated hemolysis and deposition of complement C3 proteins on red blood cells.
The most common side effects include fever, headache, increased levels of liver enzymes and pain in the extremities. Danicopan was approved for medical use in Japan in January 2024, in the United States in March 2024, and in the European Union in April 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Danicopan, sold under the brand name Voydeya, is a medication used for the treatment of paroxysmal nocturnal hemoglobinuria. It is a complement inhibitor which reversibly binds to factor D to prevent alternative pathway-mediated hemolysis and deposition of complement C3 proteins on red blood cells.
The most common side effects include fever, headache, increased levels of liver enzymes and pain in the extremities. Danicopan was approved for medical use in Japan in January 2024, in the United States in March 2024, and in the European Union in April 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1338787296 under CC BY-SA 4.0; modifications have been made.